Recent survival data from BIG 1–98, albeit not statistically significant, suggest longer follow-up and meta-analytical approaches may be required in order to determine whether the efficacy advantages of the aromatase inhibitors over tamoxifen, in terms of recurrence risk reduction, will translate into breast cancer survival benefit [5]. This evidence concerns the gene CYP19A1 and breast carcinoma.